	US 11,987,640 B2
	Anti-mesothelin antigen-binding molecules and uses thereof
Colin Correnti, Seattle, WA (US); Ashok Bandaranayake, Lake Stevens, WA (US); Christopher Mehlin, Seattle, WA (US); James M. Olson, Seattle, WA (US); and Soheil Meshinchi, Seattle, WA (US)
Assigned to Fred Hutchinson Cancer Center, Seattle, WA (US)
Filed by Fred Hutchinson Cancer Center, Seattle, WA (US)
Filed on Apr. 6, 2021, as Appl. No. 17/223,871.
Claims priority of provisional application 63/006,308, filed on Apr. 7, 2020.
Prior Publication US 2021/0309755 A1, Oct. 7, 2021
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/30 (2013.01) [C07K 16/2809 (2013.01); G01N 33/57488 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01)]

12 Claims

1. An antigen-binding molecule comprising an antigen-binding domain that specifically binds human mesothelin (MSLN), wherein the antigen-binding domain comprises three heavy chain complementarity determining regions (HCDRs) contained within a heavy chain variable region (HCVR), and three light chain complementarity determining regions (LCDRs) contained within a light chain variable region (LCVR), wherein the HCVR and the LCVR are selected from a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 1/2, 9/10, 17/18, 25/26, 33/34, and 41/42.